modern insulin analogues are a convenient new approach or tool to glycaemic control , associated with low number of hypoglycaemia and favourable weight change . a1chieve , a multinational , 24-week , non - interventional study , assessed the safety and effectiveness of insulin analogues in people with t2 dm ( n = 66,726 ) in routine clinical care . please refer to editorial titled : the a1chieve study : mapping the ibn battuta trail .. the patient characteristics for the entire cohort divided as insulin - nave and insulin users is shown in the table 1 . the majority of patients ( 81.1% ) started on or were switched to biphasic insulin aspart . other groups were insulin detemir ( n = 22 ) , insulin aspart ( n = 6 ) , basal insulin plus insulin aspart ( n = 2 ) and other insulin combinations ( n = 4 ) . overall demographic data after 24 weeks of treatment , overall hypoglycaemia decreased for both insulin user ( from 30.1 events / patient - year to 13.8 events / patient - year ) and insulin nave ( from 24.9 events / patient - year to 12.7 events / patient - year ) groups . the hypoglycaemia incidence in insulin naive group at 24 weeks was lower than that observed in insulin users at baseline . also a decrease in body weight was observed for both the groups at 24 weeks [ tables 2 and 3 ] . all parameters of glycaemic control improved from baseline to study end in the total cohort [ table 4 ] . overall efficacy data of the total cohort , 146 patients started on biphasic insulin aspart  ogld , of which 95 ( 65.1% ) were insulin nave and 51 ( 34.9% ) were insulin users . after 24 weeks of treatment , hypoglycaemic events or episodes increased for both the groups ( insulin nave : from 26.4 events / patient - year to 14.7 events / patient - year and insulin users : from 29.6 events / patient - year to 14.1 events / patient - year ) . quality of life improved at the end of the study [ tables 5 and 6 ] . biphasic insulin aspartoral glucose - lowering drug safety data all parameters of glycaemic control improved from baseline to study end in those who started on or were switched to biphasic insulin aspart for both insulin nave and insulin user groups [ table 7 ] . biphasic insulin aspartoral glucose - lowering drug efficacy data of the total cohort , 2 patients started on or were switched to basal + insulin aspart and both of them were insulin users . of the total cohort , 22 patients started on insulin detemir  ogld , of which 17 ( 77.3% ) were insulin nave and 5 ( 22.7% ) were insulin users . after 24 weeks of starting or switching to insulin detemir , hypoglycaemic events decreased for both insulin nave ( from 0.4 events / patient - year to 0.6 events / patient - year ) and insulin user ( from 2.9 events / patient - year to 1.9 events / patient - year ) group . quality of life improved at the end of 24 weeks [ tables 8 and 9 ] . insulin detemiroral glucose - lowering drug safety data all parameters of glycaemic control improved from baseline to study end in those who started on or were switched to insulin detemir  oglds for insulin - nave group [ table 10 ] . insulin detemiroral glucose - lowering drug efficacy data of the total cohort , 6 patients started on insulin aspart  ogld of which 1 ( 16.7% ) was insulin nave and 5 ( 83.3% ) were insulin users . after 24 weeks of treatment , hypoglycaemic events reduced from 13.0 events / patient - year to 0.0 events / patient - year for insulin user group [ tables 11 and 12 ] . of the total cohort , 146 patients started on biphasic insulin aspart  ogld , of which 95 ( 65.1% ) were insulin nave and 51 ( 34.9% ) were insulin users . after 24 weeks of treatment , hypoglycaemic events or episodes increased for both the groups ( insulin nave : from 26.4 events / patient - year to 14.7 events / patient - year and insulin users : from 29.6 events / patient - year to 14.1 events / patient - year ) . quality of life improved at the end of the study [ tables 5 and 6 ] . biphasic insulin aspartoral glucose - lowering drug safety data all parameters of glycaemic control improved from baseline to study end in those who started on or were switched to biphasic insulin aspart for both insulin nave and insulin user groups [ table 7 ] . of the total cohort , 2 patients started on or were switched to basal + insulin aspart and both of them were insulin users . of the total cohort , 22 patients started on insulin detemir  ogld , of which 17 ( 77.3% ) were insulin nave and 5 ( 22.7% ) were insulin users . after 24 weeks of starting or switching to insulin detemir , hypoglycaemic events decreased for both insulin nave ( from 0.4 events / patient - year to 0.6 events / patient - year ) and insulin user ( from 2.9 events / patient - year to 1.9 events / patient - year ) group . quality of life improved at the end of 24 weeks [ tables 8 and 9 ] . insulin detemiroral glucose - lowering drug safety data all parameters of glycaemic control improved from baseline to study end in those who started on or were switched to insulin detemir  oglds for insulin - nave group [ table 10 ] . of the total cohort , 6 patients started on insulin aspart  ogld of which 1 ( 16.7% ) was insulin nave and 5 ( 83.3% ) were insulin users . after 24 weeks of treatment , hypoglycaemic events reduced from 13.0 events / patient - year to 0.0 events / patient - year for insulin user group [ tables 11 and 12 ] . our study reports improved glycaemic control following 24 weeks of treatment with any of the insulin analogues ( biphasic insulin aspart ; insulin detemir ; insulin aspart ) with or without ogld . bodyweight decreased and quality of life improved after 24 weeks in the total cohort . though the findings are limited by number of patients , still the trend indicates that insulin analogues can be considered effective and possess a safe profile for treating type 2 diabetes in oriental morocco .
background : the a1chieve , a multicentric ( 28 countries ) , 24-week , non - interventional study evaluated the safety and effectiveness of insulin detemir , biphasic insulin aspart and insulin aspart in people with t2 dm ( n = 66 726 ) in routine clinical care across four continents.materials and methods : data was collected at baseline , at 12 weeks and at 24 weeks . this short communication presents the results for patients enrolled from oriental , morocco.results:a total of 180 patients were enrolled in the study . 
 four different insulin analogue regimens were used in the study . 
 study patients had started on or were switched to biphasic insulin aspart ( n = 146 ) , insulin detemir ( n = 22 ) , insulin aspart ( n = 6 ) , basal insulin plus insulin aspart ( n = 2 ) and other insulin combinations ( n = 4 ) . at baseline glycaemic control was poor for both insulin nave ( mean hba1c : 9.0% ) and insulin user ( mean hba1c : 8.8% ) groups . 
 after 24 weeks of treatment , both the study groups showed improvement in hba1c ( insulin nave : 1.7% , insulin users : 1.6% ) . 
 sadrs including major hypoglycaemia did not occur in any of the study patients.conclusion:starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia .